Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases |…

July 7, 2020 medical

DetailsCategory: More NewsPublished on Tuesday, 07 July 2020 18:18Hits: 203

INGELHEIM, Germany & WAEDENSWIL, Switzerland I July 07, 2020 I Boehringer Ingelheim and Numab Therapeutics (Numab) today announced that they have entered into a research collaboration and worldwide licensing agreement. It will start with two projects aiming at novel therapies for difficult-to-treat lung and gastrointestinal (GI) cancers and patients with geographic atrophy (GA), a progressive, irreversible retinal disease that occurs in patients with age-related macular degeneration (AMD) for which there is no current treatment. The collaboration brings together Boehringer Ingelheims leading expertise in the research and development of life changing breakthrough therapies with Numabs multi-specific antibody platform.

Lung and GI cancers and retinal diseases are key focus areas of Boehringer Ingelheims research and development program. In oncology the company has built a broad and diverse pipeline, combining cancer immunology and cancer cell directed approaches. The novel T-cell engager to be developed with Numab adds to Boehringer Ingelheims growing cancer immunology portfolio and supports the strategy to take cancer on by targeting cold tumors with synergistic combination approaches. In retinal diseases Boehringer Ingelheim is pursuing a holistic approach leveraging existing expertise in oncology, inflammation, neurodegeneration, fibrosis and cardiometabolic diseases. The new GA program with Numab further broadens the companys comprehensive portfolio of next generation retinal therapy approaches in various stages of development up to Phase 2 in macular degeneration and diabetic retinal diseases.

We are thrilled to work with the excellent team at Numab to advance our portfolio assets. Numabs technology platform fits well with our internal antibody discovery and engineering capabilities and will enhance our efforts to deliver transformative antibody-based therapeutics to patients, said Paige Mahaney, SVP and US Discovery Research Site Head at Boehringer Ingelheim.

We are looking forward to working with Boehringer Ingelheim, a global leader in pharmaceutical R&D with profound expertise across a broad spectrum of therapeutic areas, further validating our technology platform. This addition to our growing roster of partnerships represents another key milestone in our business development efforts, commented Dr. Oliver Middendorp, Chief Business Officer of Numab Therapeutics. The upfront payment and near-term milestones attached to this alliance will further strengthen Numabs ability to accelerate the development of key proprietary assets.

Under the terms of the alliance, the partners will work together to discover one novel multi-specific antibody drug candidate in each area. Boehringer Ingelheim receives from Numab an exclusive worldwide license to develop and commercialize the resulting candidates in exchange for upfront and milestone payments, as well as tiered royalties on net sales of all products resulting from the alliance.

With todays announcement, Numab has been able to secure seven ongoing relationships with leading pharmaceutical companies including 3SBio / Sunshine Guojian, Boehringer Ingelheim, Eisai Co., Ltd., CStone Pharmaceuticals, Ono Pharmaceutical Co., Ltd., Kaken Pharmaceutical Co., Ltd., and Tillotts Pharma AG.

About Boehringer IngelheimMaking new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

More information about Boehringer Ingelheim can be found at http://www.boehringer-ingelheim.com or in our annual report http://annualreport.boehringer-ingelheim.com.

About Numab TherapeuticsNumab Therapeutics is an oncology-focused biopharmaceutical company based in Zurich-area, Switzerland. At Numab, we are writing the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. With our proprietary MATCH technology platform, we are fueling a new wave of multi-specific drug candidates engineered with versatility and developability in mind. Our lead product was designed to balance potent anti-tumor immunity with a desirable safety profile by targeting 4-1BB, PD-L1 and Human Serum Albumin simultaneously. We believe meeting the highest quality standards in every step of the drug design process matters and will result in better patient outcomes. For further information, visit http://www.numab.com (link is external).

SOURCE: Numab Therapeutics

Immunology

UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA (certolizumab pegol) for the Treatment of Adults with Moderate to Severe Crohn’s…

July 7, 2020 medical

ATLANTA and PARSIPPANY, N.J., July 7, 2020 /PRNewswire/ -- UCB and Ferring Pharmaceuticals Inc. today announced they have entered into a co-promotion agreement to commercialize the prefilled syringe formulation of CIMZIA® (certolizumab pegol) in the United States, specifically for the treatment of Crohn's disease (CD). Ferring will take over marketing, sales promotion, and field medical affairs activities. UCB will continue to be responsible for all product-related activities, including revenue recognition. CIMZIA is an injectable biologic treatment option for adults with moderate to severe Crohn's disease with inadequate response to conventional therapy. UCB will continue to promote and to commercialize the lyophilized formulation of CIMZIA for all indications as well as the prefilled syringe formulation for CIMZIA's rheumatology and dermatology indications.

"UCB is committed to serving the needs of immunology patients, including those living with Crohn's disease. We are excited about this opportunity as it will expand the awareness to the benefits of CIMZIA for individuals living with moderate to severe Crohn's disease, while continuing to support patients through our services and programs," said Camille Lee, Head of U.S. Immunology at UCB. "We believe UCB and Ferring are a strategic fit for the co-promotion as both companies have a strong patient-focused commitment and Ferring has expertise in gastroenterology. UCB is preparing for future launches in immunology, demonstrating our commitment to patients with severe chronic diseases."

This co-promotion allows Ferring to expand its growing portfolio in the gastrointestinal space and support patients living with Crohn's disease, while enabling UCB to focus on and prepare for the future.

"Ferring is focusing on gut health as we expand our gastroenterology portfolio," said Brent Ragans, President of Ferring US. "Together with our existing portfolio, this agreement with UCB will allow Ferring to offer treatment options to the nearly 800,000 adult patients in the U.S. who suffer from Crohn's disease."

CIMZIA has been a treatment option for adults living with moderate to severe Crohn's disease over the last 12 years, since it was approved by the FDA in 2008 based on safety and efficacy data from clinical trials in more than 1,500 patients with Crohn's disease.

CIMZIA can be administered either through self-injection or by a healthcare professional.1 CIMZIA can lower the ability to fight infections. Some people who received CIMZIA have developed serious infections, including tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body.1 Some of these serious infections have caused hospitalization and death.1

About Crohn's disease

Crohn's disease is an inflammatory bowel disease causing chronic inflammation of the gastrointestinal (GI) tract.2 Crohn's disease can affect any part of the GI tract from mouth to anus, most commonly involving the ileum and proximal colon.3 It belongs to a group of conditions known as inflammatory bowel diseases, or IBD.4 The disease can occur at any age, but is most often diagnosed in adolescents and adults between the ages of 20 and 30.2 Approximately 780,000 Americans are currently affected by Crohn's disease.3

Patients with Crohn's disease may present acutely or have a history of symptoms prior to confirming diagnosis.4 A hallmark symptom in patients with Crohn's disease is abdominal pain.4 Other symptoms include diarrhea potentially persistent in nature,GI bleeding, urgent need to move bowels,abdominal cramps,sensation of incomplete bowel evacuationand constipation, which can lead to bowel obstruction.4

About CIMZIA® in the US

CIMZIA is the only Fc-free, PEGylated anti-TNF (Tumor Necrosis Factor). CIMZIA has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha.

CIMZIA is indicated for reducing signs and symptoms of Crohn's disease (CD) and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.

CIMZIA is also indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA), adults with active psoriatic arthritis (PsA), adults with active ankylosing spondylitis (AS), and adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.

In addition, CIMZIA is indicated for the treatment of moderate to severe plaque psoriasis (PSO) in adults who are candidates for systemic therapy or phototherapy. See important safety information including risk of serious bacterial, viral and fungal infections and tuberculosis below.

IMPORTANT SAFETY INFORMATION about CIMZIA in the U.S.

CONTRAINDICATIONS

CIMZIA is contraindicated in patients with a history of hypersensitivity reaction to certolizumab pegol or to any of the excipients. Reactions have included angioedema, anaphylaxis, serum sickness, and urticaria.

SERIOUS INFECTIONS

Patients treated with CIMZIA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue CIMZIA if a patient develops a serious infection or sepsis.

Reported infections include:

Carefully consider the risks and benefits of treatment with CIMZIA prior to initiating therapy in the following patients: with chronic or recurrent infection; who have been exposed to TB; with a history of opportunistic infection; who resided in or traveled in regions where mycoses are endemic; with underlying conditions that may predispose them to infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with CIMZIA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

MALIGNANCY

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member. CIMZIA is not indicated for use in pediatric patients.

HEART FAILURE

HYPERSENSITIVITY

HEPATITIS B VIRUS REACTIVATION

NEUROLOGIC REACTIONS

HEMATOLOGIC REACTIONS

DRUG INTERACTIONS

AUTOIMMUNITY

IMMUNIZATIONS

ADVERSE REACTIONS

For full prescribing information, please visit https://ucb-usa.com/_up/ucb_usa_com_kopie/documents/Cimzia_PI.pdf

References:

CIMZIA® is a registered trademark of the UCB Group of Companies.

For further information, Ferring Pharmaceuticals:

Heather Guzzi Director, Brand Communications (862) 286-5254 (direct) (973) 769-3999 (mobile) heather.guzzi@ferring.com

For further information, UCB: U.S. Communications Allyson Funk Communications, U.S. T. 770.970.8338, allyson.funk@ucb.com

Investor Relations Antje Witte Investor Relations, UCB T +32.2.559.94.14, antje.witte@ucb.com

Isabelle Ghellynck Investor Relations, UCB T+32.2.559.9588, isabelle.ghellynck@ucb.com

About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 600 people in approximately 40 countries, the company generated revenue of 4.9 billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCBUSA

About Ferring Pharmaceuticals Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. In the United States, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and orthopaedics. For more information, call 1-888-FERRING (1-888-337-7464); visit http://www.FerringUSA.com

Forward looking statements UCB This press release may contain forward-looking statements including, without limitation, statements containing the words "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to differ materially from those that may be expressed or implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: the global spread and impact of COVID-19, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, will progress to product approval or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.

Given these uncertainties, you should not place undue reliance on any of such forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labelling in any market, or at any particular time, nor can there be any guarantee that such products will be or will continue to be commercially successful in the future.

UCB is providing this information, including forward-looking statements, only as of the date of this press release and it does not reflect any potential impact from the evolving COVID-19 pandemic, unless indicated otherwise. UCB is following the worldwide developments diligently to assess the financial significance of this pandemic to UCB. UCB expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.

USP-CZ-CD-2000038

View original content to download multimedia:http://www.prnewswire.com/news-releases/ucb-and-ferring-pharmaceuticals-announce-co-promotion-of-cimzia-certolizumab-pegol-for-the-treatment-of-adults-with-moderate-to-severe-crohns-disease-301089326.html

SOURCE UCB, Inc.

Go here to read the rest:
UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA (certolizumab pegol) for the Treatment of Adults with Moderate to Severe Crohn's...

Immunology

Allogene Therapeutics Adds Immunotherapy Luminaries, Thomas F. Gajewski, MD, Ph.D., and Stephan Grupp, MD, Ph.D., to its Scientific Advisory Board -…

July 7, 2020 medical

SOUTH SAN FRANCISCO, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced the appointment ofThomas F. Gajewski, M.D., Ph.D., and Stephan Grupp, M.D., Ph.D. to itsScientific Advisory Board(SAB).The SAB comprises experts across oncology, immunology, cell therapy, and drug discovery and development.

We areprivileged to welcome Drs. Gajewski and Grupp to our Scientific Advisory Board, saidRafael Amado, M.D., Executive Vice President of Research & Development and Chief Medical Officer of Allogene. The additions of Dr. Gajewski and Dr. Grupp further enhance what has become one of the most distinguished cell therapy SABs in the industry and is an important component of our strategy to lead the development of allogeneic cell therapies today and tomorrow.

New Allogene SAB members:

The new advisors join existing SAB members, Chairman Ton Schumacher, Ph.D.,Donald B. Kohn, M.D., Malcolm K. Brenner, M.D., Ph.D.,Matthew Porteus, M.D., Ph.D., Owen Witte, M.D., Stephen J. Forman, M.D., and Wendell Lim, Ph.D.

About Allogene TherapeuticsAllogene Therapeutics, with headquarters inSouth San Francisco, is a clinical-stagebiotechnology company pioneering the development of allogeneic chimeric antigen receptor Tcell (AlloCAR T) therapies for cancer. Led by a management team with significantexperience in cell therapy, Allogene is developing a pipeline of off-the-shelf CAR T cell therapycandidates with the goal of delivering readily available cell therapy on-demand, more reliably, and atgreater scale to more patients. For more information, please visitwww.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements for Allogene This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T therapies for cancer and the potential benefits of AlloCAR T therapy. Various factors may cause differences between Allogenes expectations and actual results as discussed in greater detail in Allogenes filings with the SEC, including without limitation in its Form 10-Q for the quarter ended March 31, 2020. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Kymriah is a registered trademark of Novartis Pharmaceuticals Corporation.AlloCAR T is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:Christine CassianoChief Communications Officer(714) 552-0326Christine.Cassiano@allogene.com

Immunology

Aichi Cancer Center and NEC to jointly study Advanced Cancer Immunotherapy – BSA bureau

July 7, 2020 medical

Aims to improve the performance of NEC's neoantigen prediction system and developing predictive biomarkers through the fusion of AI and Experimental Immunology

Aichi Cancer Center and NEC Corporation on 6 July 2020 announced the launch of fundamental research aiming to realize the promise of advanced personalized cancer immunotherapy by improving the performance of NEC's neoantigen prediction system and developing predictive biomarkers for patient stratification through the fusion of AI and experimental immunology.

The research aims to identify suitable neoantigen for vaccine use by using the neoantigen prediction system which NEC has been working on and the screening techniques using T cells for neoantigen from Aichi Cancer Center. In addition, this research aims to develop biomarkers for patient stratification using AI based on analytical data on a tumor immune microenvironment and clinical data.

Advanced personalized cancer immunotherapy boosts the immune system especially in combination with immune checkpoint inhibitors (ICIs).

The joint research mainly focused on;

Performance improvement of the neoantigen prediction systemAichi Cancer Center and NEC will identify neoantigens recognized by T cells by using both the neoantigen prediction system and the immunological experimental approach. In the future, NEC will improve the performance of the neoantigen prediction system by using this high-quality data.

Development of biomarkers for patient stratificationAichi Cancer Center and NEC will comprehensively analyze the tumor immune microenvironment of each patient. This research aims to develop biomarkers for patient stratification using AI based on clinical information, genetic mutation, gene expression, and experimental data obtained from the experiments described above.

See the rest here:
Aichi Cancer Center and NEC to jointly study Advanced Cancer Immunotherapy - BSA bureau

Immunology

Researchers Find Promising Therapy to Fight Epidemic of Liver Disease – Mirage News

July 7, 2020 medical

So far there are no approved drugs for Non-Alcoholic Fatty Liver Disease

In an effort to combat a growing worldwide epidemic of Nonalcoholic Fatty Liver Disease (NAFLD), scientists have discovered a new target and a new therapy that has shown promising results in preclinical mouse models, according to researchers at the University of Colorado Anschutz Medical Campus.

NAFLD is a major health issue right now, a real epidemic with no treatment. It affects about 25% of the world population, said the studys lead author Mercedes Rincon, PhD, professor in the Department of Immunology and Microbiology at the University of Colorado School of Medicine. The incidence is higher in those who are obese, but it is not restricted to them.

The study was published last week in the journal Nature Communications.

NAFLD is characterized by the accumulation of fat in the liver which can lead to fibrosis and eventually Non-Alcoholic Steatohepatitis (NASH), an advanced phase of NAFLD that can cause liver failure and death. It is now the most common form of chronic liver disease with no drugs currently approved to treat it.

The researchers focused on MCJ or Methylation-Controlled J Protein as a target for NASH. This protein lives in the mitochondria, the engine of the cells, where lipids are burned in the liver. MCJ acts as a brake on the metabolic activity of the mitochondria. Patients with NAFLD often have higher MCJ levels in their livers.

But MCJ is not critical for life under normal conditions, so Rincons team decided to eliminate this metabolic brake in the liver to increase fat burning and minimize the accumulation of lipids and the development of fibrosis. They used siRNA or Small Interfering RNA to silence MCJ in the liver. This is an emerging therapeutic approach that has shown success in treating some liver diseases.

To test if siRNA for MCJ (called siMCJ) could be a potential therapeutic against NAFLD, mice in preclinical studies were fed a high-fat, high fructose diet. After months on the diet, the mice developed fatty liver. Then they were treated regularly with siMCJ or a placebo. The siMCJ group had lower levels of lipids and fibrosis in their livers compared to the control group. Using this treatment, similar reductions in lipid content and fibrosis were seen in another model on a low protein diet.

We showed that MCJ-deficient mice are resistant to the development of fatty liver and NASH, Rincon said. Importantly, using siRNA as a therapeutic approach we show that treatment with different formulations of siMCJ after the onset of the disease reduces liver steatosis and fibrosis in multiple mouse models.

A key aspect of this therapy is delivering it to the right part of the liver. The researchers combined the siRNA with GalNac, a sugar derivative that binds directly to hepatocytes, cells that make up the majority of the liver.

The result, the study said, is that MCJ is emerging as an alternative target for treating NASH and NAFLD.

Currently, most leading therapeutic drugs undergoing clinical trials for NASH are small molecules given as a systemic treatment, Rincon said. Our data show, in contrast, that the use of siRNA to reduce the levels of MCJ in the liver may constitute an alternative therapeutic strategy.

The rest is here:
Researchers Find Promising Therapy to Fight Epidemic of Liver Disease - Mirage News

Immunology

$5 million gift aims to propel Lyme disease research and education – News-Medical.Net

July 7, 2020 medical

Reviewed by Emily Henderson, B.Sc.Jul 6 2020

To the Fairbairns, the symptoms--debilitating fatigue, joint pain, cognitive problems--were as worrisome as they were mystifying. All four members of the family had them.

Eventually, all four tested positive for the bacterium that causes Lyme disease. After months of hitting diagnostic brick walls, the family had a unifying explanation for their symptoms, yet getting them under control took a year. Their conditions are now chronic, with recurrent flare-ups that require ongoing medical management.

The family's experience is not uncommon. In an effort to help spare others with the disease a similar odyssey of pain, worry and confusion, the Fairbairns have made a $5 million donation to Harvard Medical School.

The gift, which will fund three tracks, is aimed at propelling research into Lyme disease and improving public understanding of the most common vector-borne disease in the United States. Even though official reports put the annual number of Lyme disease cases at around 300,000 people per year, that number likely underestimates the true magnitude of infections and the spread of the disease. The National Institutes of Health estimates that the actual number of Lyme disease cases occurring every year is much higher.

The gift will fund the following areas:

The neuroimmunology track ($2 million) will attempt to elucidate how the bacterial pathogen behind Lyme disease may influence the interplay between immunity, inflammation and the nervous system during infection.

The mechanisms of Lyme disease track ($2 million) will study the fundamental processes that underlie the development of disease following infection with disease-causing bacteria (most commonly, Borrelia burgdorferi, and more rarely other organisms).

The education track ($1 million) will support efforts to empower the lay public through improved public understanding and prevention of the disease.

"There is growing evidence that in the setting of infection, the immune system and the nervous system engage in a complex interaction," said Isaac Chiu, who will lead the neuroimmunology research arm with colleague Jun Huh, both assistant professors of immunology in the Blavatnik Institute at HMS.

We hope to understand exactly how this happens in the setting of Lyme disease, which can in turn inform the design of therapies that can minimize tissue damage or even prevent disease development following infection with the pathogen."

Isaac Chiu, Assistant Professor of Immunology, Blavatnik Institute at HMS

The disease-mechanisms research track will investigate more broadly how the bacteria that cause Lyme disease interact with cells, tissues, and organs and can result in acute and chronic disease--knowledge that can inform new and more effective diagnostics and therapies and could help propel vaccine research. Over the next five years, this funding will support grants awarded to researchers looking at different aspects of Lyme disease at Harvard Medical School and its affiliated hospitals.

"These grants will facilitate cutting-edge, adventurous science and the ability to ask questions that are going to move the field forward in jumps instead of incremental steps," said Mark Namchuk, executive director of therapeutics translation at HMS, who will administer the disease-mechanism fund.

The education track will support efforts to inform the public about ways to prevent Lyme disease and about the latest research on the pathophysiology of the condition.

Most of the funding in the education arm will be used to develop new content for Harvard Health Publishing, which provides health information to people around the world, drawing upon the expertise of more than 11,000 Harvard Medical School faculty physicians.

"One of Harvard Medical School's core tenets is generating knowledge and disseminating it to the public," said David Roberts, dean for External Education at HMS, who will administer the education fund. "Using this far-reaching educational platform, we hope to improve the understanding of this disease and offer information that can help improve the lives of those affected."

Lyme disease is a confounding disorder. Its presentation can vary from person to person, and a diagnosis is rarely straightforward. A single tick bite can transmit multiple disease-causing organisms. Infections with more than one organism can result in widely ranging disease presentation and may alter how the immune system responds to the infection. Exactly how these coinfections affect disease presentation, symptoms and the short-term and long-term course of the disease remains largely unknown.

There are no consistently accurate tests, and most diagnoses require complex clinical assessment and astute clinical judgment in addition to testing for the causative organisms. A negative test for bacterial infection does not necessarily rule out the presence of disease. The accuracy and speed of diagnosis are further complicated by the varying range and presentation of symptoms. For people who develop lingering symptoms and chronic forms of this disease, there is no established cure and the most common treatment--several classes of oral or intravenous antibiotics--do not work reliably for everyone.

These are all areas of research that require unwavering scientific attention and sustained research efforts enabled by a steady stream of funding, the Fairbairns said.

"Historically, Lyme disease research has been woefully underfunded, and much more needs to be done to better understand this complex disease and its devastating consequences," said Emily Fairbairn, whose husband Malcolm and daughter, Nina, are both Harvard University alumni. The youngest family member, Grant, is expected to graduate from Harvard College in 2021.

"Per-patient NIH funding for Lyme disease research amounts to less than $90 per newly diagnosed patient per year, and this is precisely why private philanthropy is crucial," Emily Fairbairn added. "This disease needs billions of dollars, not millions. We are hoping that this investment will make strides that will attract even more funding to better understand, prevent and treat this important disease."

The Fairbairn family previously donated $1 million to the laboratory of geneticist George Church to support research into the genomics of Lyme disease.

Read the rest here:
$5 million gift aims to propel Lyme disease research and education - News-Medical.Net

Biochemistry

Biochemist – Career Rankings, Salary, Reviews and Advice …

July 7, 2020 medical

Biochemistry delves into the chemical processes of living organisms. In other words, biochemists apply their knowledge of chemicals and perform different chemical techniques and experiments to decipher biological problems.

People who thrive on finding solutions to problems and are science-minded are a good fit for this profession. One of those people is Bruce Alberts, who grew up reading Sinclair Lewis' "Arrowsmith," a novel about a rags-to-riches American doctor who makes a great scientific discovery. "Everybody in my generation who became a scientist read 'Arrowsmith,'" Alberts laughs. "It provided an idealistic view of what our future could be like as a scientist." However, similar to the protagonist in the novel, Alberts first set out to be a doctor.

Alberts got into Harvard University and started down the premed track. He enjoyed his courses, especially physical chemistry, but he loathed the formulaic laboratory portions that accompanied them. He likened these labs more to cooking classes than to science. But one of those boring labs would forever change the course of his career.

The labs were "not even vaguely interesting," Alberts says, so during his junior year he petitioned the school to get out of all of the course labs. The school administrators rejected his petition, but they said Alberts could switch into a research lab instead. And there, among the doctoral students and post-docs who were performing experiments and completing exciting research, he found his true calling. The summer between his junior and senior year at Harvard, he worked 100-hour weeks in the research lab. And instead of applying to medical schools, he applied to Ph.D. programs.

Today, Alberts' resume could cover just about as many pages as the novel he read as a kid. Alberts' research has centered on "the functions of a set of proteins that form the protein machine that carries out chromosomal replication." He has also taught at Princeton and the University of California-San Francisco. He's co-written several iterations of well-regarded textbooks, including "Molecular Biology of the Cell" and "Essential Cell Biology." He has served as the editor-in-chief of "Science" magazine and as the president of the National Academy of Sciences. He also served as a United States Science Envoy. In 2014, President Obama awarded him the National Medal of Science.

But after all these years of important positions and accolades, his favorite part of his career is finding solutions to problems.

"Like all scientists, I get pleasure out of solving problems," Alberts says. But these days, he's concentrating on getting kids to understand and develop an interest in science. "The chemistry of life is incredibly complex. A living cell is the most amazing thing in the universe," he says. And he hopes that by creating a new curriculum, built on inquiry-based learning, which is basically getting children to ask questions of the world and answer them on their own, kids too will see the wonder and magic of science.

The Bureau of Labor Statistics projects 6.3 percent employment growth for biochemists between 2018 and 2028. In that period, an estimated 1,900 jobs should open up.

More here:
Biochemist - Career Rankings, Salary, Reviews and Advice ...

Biochemistry

Automatic Biochemistry Analyzers Market Growth By Manufacturers, Type And Application, Forecast To 2026 – 3rd Watch News

July 7, 2020 medical

New Jersey, United States,- Market Research Intellect sheds light on the market scope, potential, and performance perspective of the Global Automatic Biochemistry Analyzers Market by carrying out an extensive market analysis. Pivotal market aspects like market trends, the shift in customer preferences, fluctuating consumption, cost volatility, the product range available in the market, growth rate, drivers and constraints, financial standing, and challenges existing in the market are comprehensively evaluated to deduce their impact on the growth of the market in the coming years. The report also gives an industry-wide competitive analysis, highlighting the different market segments, individual market share of leading players, and the contemporary market scenario and the most vital elements to study while assessing the global Automatic Biochemistry Analyzers market.

The research study includes the latest updates about the COVID-19 impact on the Automatic Biochemistry Analyzers sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Leading Automatic Biochemistry Analyzers manufacturers/companies operating at both regional and global levels:

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=254034&utm_source=3WN&utm_medium=888

The Automatic Biochemistry Analyzers market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Automatic Biochemistry Analyzers market.

This study analyzes the growth of Automatic Biochemistry Analyzers based on the present, past and futuristic data and will render complete information about the Automatic Biochemistry Analyzers industry to the market-leading industry players that will guide the direction of the Automatic Biochemistry Analyzers market through the forecast period. All of these players are analyzed in detail so as to get details concerning their recent announcements and partnerships, product/services, and investment strategies, among others.

Sales Forecast:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Automatic Biochemistry Analyzers market. Additionally, it includes a share of each segment of the Automatic Biochemistry Analyzers market, giving methodical information about types and applications of the market.

Reasons for Buying Automatic Biochemistry Analyzers Market Report

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It renders an in-depth analysis for changing competitive dynamics.

It presents a detailed analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by performing a pin-point analysis of market segments and by having complete insights of the Automatic Biochemistry Analyzers market.

This report helps the readers understand key product segments and their future.

Have Any Query? Ask Our Expert @ https://www.marketresearchintellect.com/need-customization/?rid=254034&utm_source=3WN&utm_medium=888

In the end, the Automatic Biochemistry Analyzers market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.

To summarize, the global Automatic Biochemistry Analyzers market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Plastic Surgery Instruments Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Protein Binding Assay Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Q-Tof Mass Spectrometry Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Veterinary Endoscopy Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Autoinjectors Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

More:
Automatic Biochemistry Analyzers Market Growth By Manufacturers, Type And Application, Forecast To 2026 - 3rd Watch News

Biochemistry

Automatic Veterinary Biochemistry Analyzer Market Growth By Manufacturers, Type And Application, Forecast To 2026 – 3rd Watch News

July 7, 2020 medical

New Jersey, United States,- The latest research study on Automatic Veterinary Biochemistry Analyzer Market Added by Market Research Intellect, offers details on current and future growth trends pertaining to the business besides information on myriad regions across the geographical landscape of the Automatic Veterinary Biochemistry Analyzer market. The report also expands on comprehensive details regarding the supply and demand analysis, participation by major industry players and market share growth statistics of the business sphere.

The research report on the Automatic Veterinary Biochemistry Analyzer market provides a granular assessment of this business vertical and includes information concerning the market tendencies such as revenue estimations, current remuneration, market valuation, and market size over the estimated timeframe.

Download Sample Copy of Automatic Veterinary Biochemistry Analyzer Market Report Study 2020-2027 @ https://www.marketresearchintellect.com/download-sample/?rid=148824&utm_source=3WN&utm_medium=888

Major Players Covered in this Report are:

The research report is broken down into chapters, which are introduced by the executive summary. Its the introductory part of the chapter, which includes details about global market figures, both historical and estimates. The executive summary also provides a brief about the segments and the reasons for the progress or decline during the forecast period. The insightful research report on the global Automatic Veterinary Biochemistry Analyzer market includes Porters five forces analysis and SWOT analysis to understand the factors impacting consumer and supplier behavior.

The scope of the Report:

The report segments the global Automatic Veterinary Biochemistry Analyzer market on the basis of application, type, service, technology, and region. Each chapter under this segmentation allows readers to grasp the nitty-gritty of the market. A magnified look at the segment-based analysis is aimed at giving the readers a closer look at the opportunities and threats in the market. It also addresses political scenarios that are expected to impact the market in both small and big ways. The report on the global Automatic Veterinary Biochemistry Analyzer market examines changing regulatory scenarios to make accurate projections about potential investments. It also evaluates the risk for new entrants and the intensity of the competitive rivalry.

In Market Segmentation by Types of Automatic Veterinary Biochemistry Analyzer, the report covers-

In Market Segmentation by Applications of the Automatic Veterinary Biochemistry Analyzer, the report covers the following uses-

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=148824&utm_source=3WN&utm_medium=888

As per the regional scope of the Automatic Veterinary Biochemistry Analyzer market:

Highlights of the report:

Key Questions Answered in the report:

Have Any Query? Ask Our Expert @ https://www.marketresearchintellect.com/need-customization/?rid=148824&utm_source=3WN&utm_medium=888

In the end, the Automatic Veterinary Biochemistry Analyzer market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.

To summarize, the global Automatic Veterinary Biochemistry Analyzer market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Continued here:
Automatic Veterinary Biochemistry Analyzer Market Growth By Manufacturers, Type And Application, Forecast To 2026 - 3rd Watch News

Biochemistry

Bench-top Veterinary Biochemistry Analyzers Market Growth By Manufacturers, Type And Application, Forecast To 2026 – 3rd Watch News

July 7, 2020 medical

New Jersey, United States,- Market Research Intellect sheds light on the market scope, potential, and performance perspective of the Global Bench-top Veterinary Biochemistry Analyzers Market by carrying out an extensive market analysis. Pivotal market aspects like market trends, the shift in customer preferences, fluctuating consumption, cost volatility, the product range available in the market, growth rate, drivers and constraints, financial standing, and challenges existing in the market are comprehensively evaluated to deduce their impact on the growth of the market in the coming years. The report also gives an industry-wide competitive analysis, highlighting the different market segments, individual market share of leading players, and the contemporary market scenario and the most vital elements to study while assessing the global Bench-top Veterinary Biochemistry Analyzers market.

The research study includes the latest updates about the COVID-19 impact on the Bench-top Veterinary Biochemistry Analyzers sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Leading Bench-top Veterinary Biochemistry Analyzers manufacturers/companies operating at both regional and global levels:

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=359649&utm_source=3WN&utm_medium=888

The Bench-top Veterinary Biochemistry Analyzers market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Bench-top Veterinary Biochemistry Analyzers market.

This study analyzes the growth of Bench-top Veterinary Biochemistry Analyzers based on the present, past and futuristic data and will render complete information about the Bench-top Veterinary Biochemistry Analyzers industry to the market-leading industry players that will guide the direction of the Bench-top Veterinary Biochemistry Analyzers market through the forecast period. All of these players are analyzed in detail so as to get details concerning their recent announcements and partnerships, product/services, and investment strategies, among others.

Sales Forecast:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Bench-top Veterinary Biochemistry Analyzers market. Additionally, it includes a share of each segment of the Bench-top Veterinary Biochemistry Analyzers market, giving methodical information about types and applications of the market.

Reasons for Buying Bench-top Veterinary Biochemistry Analyzers Market Report

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It renders an in-depth analysis for changing competitive dynamics.

It presents a detailed analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by performing a pin-point analysis of market segments and by having complete insights of the Bench-top Veterinary Biochemistry Analyzers market.

This report helps the readers understand key product segments and their future.

Have Any Query? Ask Our Expert @ https://www.marketresearchintellect.com/need-customization/?rid=359649&utm_source=3WN&utm_medium=888

In the end, the Bench-top Veterinary Biochemistry Analyzers market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.

To summarize, the global Bench-top Veterinary Biochemistry Analyzers market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Automotive Hydrostatic Fan Drive System Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Automotive Ignition Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Automotive Interior Materials Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Automotive Interior Plastic Components Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Automotive Knee Airbags Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

More here:
Bench-top Veterinary Biochemistry Analyzers Market Growth By Manufacturers, Type And Application, Forecast To 2026 - 3rd Watch News